BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
peucedanum and smilax share 4963 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.692 means 69% of the combined target set is bound by both compounds. The IDF-weighted score of 0.659 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do peucedanum and smilax have in common?
peucedanum and smilax share 4963 molecular targets with a Jaccard similarity of 69%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can peucedanum and smilax be combined?
peucedanum and smilax share 4963 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: peucedanum or smilax?
In the BiohacksAI corpus: peucedanum has 156 PubMed-indexed studies, smilax has 143 studies.